A unique partnership announced today by the pharmaceutical industry and Greater Manchester Health and Social Care Partnership will help the city region deliver its vision to be the safest and most effective place to receive medicines in the world – and cement its position on the global research and development map.
The collaboration, in the form of a Memorandum of Understanding, will create a Greater Manchester and Pharmaceutical Industry Partnership Group. The group will improve the use and safety of medicines and use the unique data and information capabilities of the NHS to discover, develop, and deliver new medicines and treatments for patients.
The agreement will allow Greater Manchester to explore new ways of paying for medicines based on patient outcomes - enabling the £1 billion spent on medicines in the region to be as effective as possible.
And it sets out how industry will partner with Greater Manchester to enable the development of a world-leading site for the research and launch of new medicines.
It will be formally launched on the same day 14 multinational companies come to Manchester at a global industry seminar, an event which reflects the city region's aspiration to be a key international location for the growth of jobs and investment in the thriving life sciences industry, rivalling the 'golden triangle' of Cambridge, Oxford and London.
Jon Rouse is Chief Officer of Greater Manchester Health and Social Care Partnership. He said:
"Our ambition is to be the safest and most effective place to receive medicines in the world and this unique step will help us on that journey. We want to be able to improve people's health, get the very best value for money from our medicines budget and continue to raise Greater Manchester's profile as a global hub for investment in research and development.
"The agreement is a first step; there are some important principles we will observe and much still to be done but it shows the power of collaboration we're harnessing in Greater Manchester. When we come together then we can really grasp the opportunities devolution has given us."
Mike Thompson, CEO of the Association of the British Pharmaceutical Industry, said:
"The Pharmaceutical Industry is proud to be signing this Memorandum of Understanding with Greater Manchester. The Industry recognises the challenges faced by the NHS and we are committed to supporting improvements in the use of medicines that can enhance the care and wellbeing of people in the area.
"We can see from initiatives like the Salford Lung Study how the NHS can embrace innovation to help improve health outcomes. In Greater Manchester we have the infrastructure in place to go even further and create one of the world's pre-eminent hubs for life sciences research and investment from global companies. By working together with the NHS to improve how to use and learn from real time health data in hospitals and communities we have the best chance of creating the most appropriate and cost-effective medicines for patients in Greater Manchester and throughout the UK."
Rowena Burns Chair of Health Innovation Manchester said
"Our goal is to improve the health of Greater Manchester citizens by working more effectively with industry. This MOU represents a brilliant first step toward this goal, and sets out our commitment to work with the pharmaceutical industry to deliver new medicines to patients more quickly, to make more effective use of existing medicines, and to increase the number of real world clinical trials in Greater Manchester, which will benefit patients and bring additional economic benefits to the region.
"We are delighted that the ABPI shares our ambition, and recognises the regions exceptional academic and clinical assets and our emerging world class informatics infrastructure. Together we can make a real difference to the health of our patient population."
The Memorandum will be signed between at today's meeting of Greater Manchester Health and Social Care Strategic Partnership Board by a number of partners: Greater Manchester Health and Social Care Partnership (the Partnership), Greater Manchester Combined Authority, Health Innovation Manchester, the Association of the British Pharmaceutical Industry (ABPI), Ethical Medicines Industry Group (EMIG), and the British Generic Manufacturers Association (BGMA).
A number of proposals which have the potential to improve care for people in Greater Manchester are currently being discussed under the MOU and some are already underway. For example Greater Manchester has already started a diabetes programme with a number of pharmaceutical companies. This work reviews care and supports people to take their medicine better and improve how they live with diabetes. As asthma study is also underway and discussions about four other potential studies are now taking place.
The MOU can be found with the Partnership's Board papers at www.gmhsc.org.uk/strategic_partnership_board_meetings/meetings/ and the meeting is live streamed from 10am at www.greatermanchester-ca.gov.uk/info/20084/watch_live_board_meetings
Salford Lung Study
Greater Manchester is already the global leader in real time clinical trials. New relationships are developing, building on the success and learnings from the pioneering Salford Lung Study.
The research study involved 2,802 patients with chronic obstructive pulmonary disease (COPD) and 3,000 specially trained health care staff across 80 GP practices and 130 pharmacies in Salford and South Manchester.
Sponsored by pharmaceutical company GSK and delivered in partnership with healthcare organisations in Greater Manchester, the ground-breaking study was the world's first Randomised Controlled Trial (RCT) that used a single electronic medical record linking primary care, secondary care and pharmacy data. The study included a broad and inclusive population of patients in an everyday clinical practice setting, embracing a novel approach to clinical trial design.
The reason this could take place in this way was because of the Salford integrated electronic healthcare record. This enabled patients to be identified and followed through the process far more easily than in other trials. It also provided researchers with a breadth of clinical data about how patients use their medicines. It was designed to be as close to real life care for patients and clinicians, so that the only difference between the two groups was that one used the new inhaler and the control group received what they agreed with their clinician was most suitable for them.
The study showed that eight per cent fewer patients taking the new inhaler experienced moderate or severe problems caused by COPD, ranging from worsening of respiratory symptoms that led to treatment with medication, hospital admissions or clinic visits.
ABPI Press Office Email: email@example.com Telephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441 Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
Greater Manchester Health and Social Care Partnership
Email firstname.lastname@example.org tel 0161 625 7463
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
About Greater Manchester Health and Social Care Partnership
Greater Manchester Health and Social Care Partnership is the body made up of the 37 NHS organisations and local authorities in the city region, overseeing the £6bn devolved health and social care budget here. More information at www.gmhsc.org.uk
About Health Innovation Manchester
Health Innovation Manchester (HInM) is a partnership between the region's academic and research institutions, our social care and NHS providers, and industry. Our purpose is to align the strengths of this partnership to the health needs of GM's 2.7m citizens, and accelerate the discovery, development, and delivery of innovations which will keep citizens in good health and improve treatments and outcomes for those in ill-health.
HInM's added value as a partnership is to create a "one team" approach to tackling Greater Manchester health challenges, by:
Providing a single powerful brand for all GM partners' work on health innovation, which will attract the best industry partners from across the world
Working with partners to agree a clear and shared set of health improvement goals where innovation is both necessary and possible
Supporting the shift toward a more joined-up, person-centred approach to innovations across the entire population health, primary, secondary and social care systems
Providing straightforward, agile, system wide processes to support industry innovators with new products or services to get trials underway, and to ensure that successful trials are followed quickly by implementation across Greater Manchester
Salford Lung Study - published in the New England Journal of Medicine
Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice, Vestbo J et al, N Engl J Med 2016; 375:1253-1260September 29, 2016DOI: 10.1056/NEJMoa1608033